Rituximab for treatment of inhibitors in haemophilia A

Summary

The development of antibodies against infused factor VIII (FVIII) in patients with haemophilia A is a serious complication leading to poorly controlled bleeding and increased morbidity. No treatment has been proven to reduce high titre antibodies in patients who fail immune tolerance induction or are not candidates for it. The Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (RICH) study was a phase II trial to assess whether rituximab can reduce anamnestic FVIII antibody (inhibitor) titres. Male subjects with severe congenital haemophilia A and an inhibitor titre ≥5 Bethesda Units/ml (BU) following a FVIII challenge infusion received rituximab 375 mg/m² weekly for weeks 1 through 4. Post-rituximab inhibitor titres were measured monthly from week 6 through week 22 to assess treatment response. Of 16 subjects who received at least one dose of rituximab, three (18.8%) met the criteria for a major response, defined as a fall in inhibitor titre to <5 BU, persisting after FVIII re-challenge. One subject had a minor response, defined as a fall in inhibitor titre to <5 BU, increasing to 5–10 BU after FVIII re-challenge, but <50% of the original peak inhibitor titre. Rituximab is useful in lowering inhibitor levels in patients, but its effect as a solo treatment strategy is modest. Future studies are indicated to determine the role of rituximab as an adjunctive therapy in immune tolerisation strategies.

Trial: “Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A: The RICH Study. Registered as Clinical Trials.gov identifier- NCT00331006.

Keywords

Anti-CD20 - antibodies - monoclonal - murine-derived - blood coagulation inhibitor - CD20 antibody - haemophilia A

• References

• 1 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 09: 418-435.
• 2 Gouw SC, van der Bom JG, Ljung R. et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-239.
• 3 Hay CR, Ludlam CA, Colvin BT. et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-766.
• 4 Ewenstein BM, Gomperts ED, Pearson S. et al. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study. Haemophilia 2004; 10: 491-498.
• 5 Gringeri A, Mantovani LG, Scalone L. et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-2363.
• 6 Morfini M, Haya S, Tagariello G. et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-612.
• 7 Soucie JM, Cianfrini C, Janco RL. et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103: 2467-2473.
• 8 Hay CRM, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-1344.
• 9 Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77 (Suppl. 01) 25-27.
• 10 DiMichele DM, Kroner BL. The North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-57.
• 11 Lenk H. The German Registry of immune tolerance treatment in hemophilia--1999 update. Haematologica 2000; 85 (10) Suppl 45-47.
• 12 Haya S, López MF, Aznar JA. et al. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia 2001; 07: 154-159.
• 13 McLaughlin P, Grillo-López AJ, Link BK. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four doses treatment program. J Clin Oncol 1998; 16: 2825-2833.
• 14 Barcellini W, Zaja F, Zaninoni A. et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood 2012; 119: 3691-3697.
• 15 Froissart A, Buffet M, Veyradier A. et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Micro-angiopathies Reference Center. Crit Care Med 2012; 40: 104-111.
• 16 Stasi R, Del Poeta G, Stipa E. et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110: 2924-2930.
• 17 Ahmed AR, Spigelman Z, Cavacini LA. et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772-1779.
• 18 Smith KG, Jones RB, Burns SM. et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54: 2970-2982.
• 19 Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol 2007; 63: 47-52.
• 20 Huth-Kühne A, Baudo F, Collins P. et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94: 566-575.
• 21 Boles JC, Key NS, Kasthuri R. et al. Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia. J Thromb Haemost 2011; 09: 1429-1431.
• 22 Collins P, Baudo F, Knoebl P. et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012; 120: 47-55.
• 23 Linde R, Escuriola Ettinghausen C, Voigt B. et al. First successful inhibitor elimination with a new protocol in a high responding hemophilia A - patient after failure of various immune tolerance induction regimens. Blood 2001; 98: 534a.
• 24 Medeiros BC, Geraghty S, Stabler SP. Improved response to immune tolerance therapy for factor VIII inhibitor after rituximab therapy. Blood 2002; 100: 103b.
• 25 Pruthi RK, Schmidt KA, Slaby JA. et al. Rituximab in treatment of high titer FVIII inhibitor in congenital hemophilia A. Blood 2002; 100: 104b.
• 26 Fox RA, Neufeld EJ, Bennett CM. Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia 2006; 12: 218-222.
• 27 Mateo J, Badell I, Forner R. et al. Successful suppression using Rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: an example of a significant decrease of treatment costs. Thromb Haemost 2006; 95: 386-387.
• 28 Moschovi M, Aronis S, Trimis G. et al. Rituximab in the treatment of high responding inhibitors in severe haemophilia A. Haemophilia 2006; 12: 95-99.
• 29 Carcao M, St Louis J, Poon MC. et al. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006; 12: 7-18.
• 30 Mathias M, Khair K, Hann I. et al. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366-368.
• 31 Collins P, Mathias M, Hanley J. et al. Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. J Thromb Haemost 2009; 07: 787-794.
• 32 Franchini M, Mengoli C, Lippi G. et al. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients’ analysis. Haemophilia 2008; 14: 903-912.
• 33 Chuansumrit A, Husapadol S, Wongwerawattanakoon P. et al. Rituximab as an adjuvant therapy to immune tolerance in a haemophilia A boy with high inhibitor titre. Haemophilia 2007; 13: 108-110.
• 34 Chang H, Sher GD, Blanchette VS. et al. The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada. Haemophilia 1999; 05: 247-252.
• 35 Goudemand J. Pharmaco-economic aspects of inhibitor treatment. Eur J Haematol Suppl 1998; 63: 24-27.
• 36 Globe DR, Cunningham WE, Andersen R. et al. The Hemophilia Utilization Group Study (HUGS): determinants of costs of care in persons with haemophilia A. Haemophilia 2003; 09: 325-331.
• 37 Tony HP, Burmester G, Schulze-Koops H. et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011; 13: R75.
• 38 Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010; 47: 187-189.